Genetically Engineered Tumor Vaccines
- 1 August 1993
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 690 (1) , 301-310
- https://doi.org/10.1111/j.1749-6632.1993.tb44018.x
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.The Journal of Experimental Medicine, 1992
- A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.The Journal of Experimental Medicine, 1992
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28Science, 1991
- Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cellsCancer Immunology, Immunotherapy, 1990
- Expression of Epstein–Barr Virus Transformation–Associated Genes in Tissues of Patients with EBV Lymphoproliferative DiseaseNew England Journal of Medicine, 1989
- Abrogation of metastatic properties of tumour cells by de novo expression of H–2K antigens following H–2 gene transfectionNature, 1985
- Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformationNature, 1984